| Literature DB >> 23891189 |
Karina Lani Silva1, Paloma Silva de Souza, Gabriela Nestal de Moraes, Arthur Moellmann-Coelho, Flavia da Cunha Vasconcelos, Raquel Ciuvalschi Maia.
Abstract
P-glycoprotein (Pgp) and XIAP co-expression has been discussed in the process of the acquisition of multidrug resistance (MDR) in cancer. Here, we evaluated XIAP and Pgp expression in chronic myeloid leukemia (CML) samples, showing a positive correlation between them. Furthermore, we evaluated the effects of imatinib in XIAP and Pgp expression using CML cell lines K562 (Pgp(-)) and K562-Lucena (Pgp(+)). Imatinib increased XIAP and Pgp expression in K562-Lucena cells, while in K562 cells a downregulation of these proteins was observed, suggesting that imatinib induces an increment of MDR phenotype of CML cells that previously exhibit high levels of Pgp/XIAP co-expression.Entities:
Keywords: CML; CSA; Chronic myeloid leukemia; IAPs; IC(50); Imatinib; MDR; MFI; Multidrug resistance; P-glycoprotein; Pgp; RFI; Rho-123; Survivin; VRP; XIAP; chronic myeloid leukemia; concentration achieving 50% inhibition of cell growth; cyclosporin A; inhibitor of apoptosis proteins; mean of fluorescence intensity; multidrug resistance; ratio of mean of fluorescence intensity; rhodamine-123; verapamil
Mesh：
Substances：
Year: 2013 PMID： 23891189 DOI： 10.1016/j.leukres.2013.06.014
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156